Can-Fite BioPharma (CANF) Liabilities and Shareholders Equity (2013 - 2025)

Can-Fite BioPharma (CANF) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $9.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 4.32% year-over-year to $9.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.3 million (down 5.63% YoY) and the FY2025 annual result came in at $9.5 million, up 4.32% from the prior year.
• Liabilities and Shareholders Equity rose to $9.5 million in Q4 2025, from $7.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $20.3 million in Q4 2021 to a low of $5.9 million in Q2 2024.
• A 5-year average of $11.7 million and a median of $10.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 112.67% — and 2022, when it slumped 54.16%.
• Tracing CANF's Liabilities and Shareholders Equity over 5 years: stood at $20.3 million in 2021, then tumbled by 54.16% to $9.3 million in 2022, then climbed by 7.61% to $10.0 million in 2023, then slipped by 8.7% to $9.1 million in 2024, then advanced by 4.32% to $9.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $9.5 million (Q4 2025), $7.7 million (Q2 2025), and $9.1 million (Q4 2024), per Business Quant data.